A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
422actual
Sites
128
Countries
China, Malaysia, Mexico +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-22 | actual | When the study began enrolling |
| Primary completion | 2026-03-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-03 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Drug: BDA MDI HFO 160/180 μg
- Drug: BDA MDI HFA 160/180 μg
- Drug: Placebo MDI HFA
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29
measured Change from baseline at Day 29
Change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29
measured Change from baseline at Day 29
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed